Skip to main content
19, Oct 2020
Plexision Awarded Competitive Grant from the National Science Foundation for COVID-19 Immunity Test Development

Plexision has been awarded a National Science Foundation (NSF) Phase 1 Small Business Innovation Research Grant.

Read more
11, Sep 2014
FDA Approves PleximmuneTM For Personalized Prediction of Transplant Rejection in Children
PITTSBURGH, Sept. 11, 2014 /PRNewswire-iReach/ -- Today the FDA announced approval of PleximmuneTM
Read more
27, Nov 2013
Prognostic cell-based assay predicts acute cellular rejection in pre- and post-transplant testing...
Chethan Ashokkumar1, Rafia Khan1, Kyle A. Soltys1,Geoffrey Bond1, George V. Mazariegos1, Brandon W. Higgs1, Rakesh Sindhi1 INSTITUTIONS (ALL): 1. Children's Hospital of Pgh of UPMC, Pittsburgh, PA, United States.
Read more
11, Nov 2013
Plexision’s Pharmacokinetics (PK)/Pharmacodynamics (PD) solutions presented at Cambridge Healthtech...

Novel antibody-drug conjugates (ADC), some with dual cellular targets, are revolutionizing the delivery of potentiall

Read more
3, Nov 2013
PleximmuneTM test to predict liver transplant rejection presented at the Liver meeting...
The PleximmuneTM test is the first blood test of its kind to predict whether acute cellular rejection will occur in children with liver or intestine transplantation.
Read more
22, Oct 2013
American Transplant Congress, Seattle-scientific exchange between the various disciplines...
The American Transplant Congress was held between May 18-22 in Seattle this year. The American Transplant Congress is the premier venue for scientific exchange between the various disciplines uniquely involved in solid organ transplantation.
Read more
2, Aug 2013
ESOT Congress, Vienna-Plexision’s pharma collaboration to be reported ...
Results from Plexision’s pharma collaboration to be reported at the European Society for Organ Transplantation Congress, Vienna | September 8-11
Read more
28, Feb 2013
Combined Biomarker and Drug Development-A range of antigen-specific and non-specific cell-based assays
Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development, from preclinical to post-marketing.
Read more
23, Feb 2013
Technology - How It Works? predicts whether immunological disease will occur with tests which are highly specific for that disease.
Traditional tests for immunologic diseases measure disease activity with non-specific injury markers, markers of fully evolved injury, or by measuring the disease agent itself. A need exists to predict whether immunological disease will occur with tests which are highly specific for that disease.
Read more
Subscribe to Media

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact